FTC gets new power to block drug-switching schemes that block generics

What it does

This bill amends the Federal Trade Commission Act to prohibit pharmaceutical manufacturers from engaging in 'product hopping'—a practice where a drug maker withdraws or disadvantages an older drug to force patients and insurers onto a newer, similar version, blocking generic or biosimilar competition. The FTC gains explicit authority to sue manufacturers for this conduct and seek financial penalties (disgorgement and restitution). Manufacturers can defend their actions if they prove they had legitimate safety, supply, or pro-competitive reasons unrelated to blocking generics.

Why we flagged it

The bill's core mechanism is a new FTC enforcement power targeting a specific anticompetitive practice (product hopping) in pharmaceutical markets. It is a targeted antitrust measure, not a broad deregulation or subsidy.

What the text implies

• The 180-day/3-year window creates a narrow enforcement window; conduct outside this period may escape liability even if anticompetitive.
• Manufacturers can defend by claiming 'legitimate pro-competitive reasons' — a standard that may be litigated extensively, creating uncertainty in enforcement.
• The bill does not address pay-for-delay settlements or other reverse-payment schemes; product hopping is only one anticompetitive tactic in pharma.
• Disgorgement and restitution are capped at 5 years from the latest unjust enrichment date, potentially limiting recovery for long-running schemes.
• The FTC's burden to prove 'objective circumstances' of anticompetitive intent may be high, especially for soft switches involving marketing decisions.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Ordinary citizens benefit through lower drug costs and faster generic/biosimilar entry when product hopping is blocked. The bill restrains pharmaceutical manufacturers' ability to use switching tactics to extend monopoly pricing, directly protecting consumers and public health budgets. The enforcement mechanism is transparent and includes judicial review safeguards.

Who stands to gain

• generic drug manufacturers
• biosimilar manufacturers
• health insurers and pharmacy benefit managers
• consumers and public health programs

Named in the bill

Federal Trade Commission (FTC), FDA (Food and Drug Administration), pharmaceutical manufacturers, generic drug manufacturers, biosimilar manufacturers, US Court of Appeals, District Courts

Where it stands

3 cosponsors: 2 Democrats, 1 Republicans.

• Mar 13, 2025 — Introduced · Congress.gov: “Introduced in Senate”
• Mar 13, 2025 — Referred to Senate Committee on the Judiciary · Congress.gov: “Read twice and referred to the Committee on the Judiciary”
• Apr 3, 2025 — Reported out of committee · Congress.gov: “Committee on the Judiciary. Ordered to be reported with an amendment favorably”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

32 lobbying clients named this bill on 54 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $31,104,924 in lobbying spend. A filing names 13 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 98% of bills with at least one filing.

John Cornyn, the sponsor, reported $2,042,484 in PAC receipts in the 2026 cycle. $35,500 of that came from 5 PACs tied to these lobbying clients.

• Pharmaceutical Research and Manufacturers of America — $15,770,000 on 2 filings
• Abbvie Inc. — $2,490,000 on 2 filings
• Amgen Inc — $2,440,000 on 1 filing
• Blue Cross and Blue Shield Association — $2,430,000 on 2 filings
• Johnson & Johnson Services Inc — $1,440,000 on 1 filing

Lobbying Disclosure Act filings through Jul 22, 2026. A filing shows who paid to lobby on a bill it names, not what changed.